2.77
Spero Therapeutics Inc Aktie (SPRO) Neueste Nachrichten
Spero Therapeutics Stock (US85208T1079): Quiet session keeps focus on fundamentals and pipeline - AD HOC NEWS
SPRO News | SPERO THERAPEUTICS INC (NASDAQ:SPRO) - ChartMill
Spero Therapeutics: Approval Upside, Commercial Friction (Initiating Hold) - Seeking Alpha
Spero Therapeutics Q1 2026 Earnings: Narrower Loss Beats Estimates, but Stock Falls Amid Lack of Revenue - newsline.com
MSN Money - MSN
Spero Therapeutics (SPRO) Slips 2.41% as Stock Tests Key Support at $2.69Dark Pool Volume - newsline.com
Spero Therapeutics (SPRO) Hovers Near Support Amid Modest Decline – Key Levels in FocusCorrective Wave - The Legal Advocate
Spero Therapeutics (SPRO) Jumps 4.9% as Stock Approaches Key Resistance at $3.15Oversold Bounce Ideas - The Legal Advocate
SPRO Technical Analysis | Trend, Signals & Chart Patterns | SPERO THERAPEUTICS INC (NASDAQ:SPRO) - ChartMill
Spero Therapeutics (SPRO) Q1 2026 Earnings: Why the Beat MattersCEO Earnings Statement - Newser
Spero Therapeutics, Inc. Common Stock (SPRO) Stock Price Today & Analysis - Gotrade
Promising Penny Stocks To Consider In May 2026 - simplywall.st
Is Spero Therapeutics (SPRO) 110.3% Overvalued After Q1 2026 Ear - GuruFocus
Spero Therapeutics 1Q Loss $7.2M >SPRO - Moomoo
Spero Therapeutics Q1 revenue drops on decreased clinical activity - TradingView
Spero Therapeutics Announces First Quarter 2026 Operating Results and Provides Business Update - The Manila Times
Spero Therapeutics (NASDAQ: SPRO) leans on GSK-partnered tebipenem ahead June 2026 FDA date - Stock Titan
Spero Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Spero Therapeutics (SPRO) trims Q1 2026 loss ahead key tebipenem FDA date - Stock Titan
TradingKey - TradingKey
Number of shareholders of Spero Therapeutics, Inc. – NASDAQ:SPRO - TradingView
SPRO SEC FilingsSpero Therapeuti 10-K, 10-Q, 8-K Forms - Stock Titan
SPRO FINAL DEADLINE TODAY: ROSEN, A GLOBALLY RECOGNIZED FIRM, Encourages Spero Therapeutics, Inc. Investors with Losses to Secure Counsel Before Important July 25 Deadline in Securities Class ActionSPRO - TMX Newsfile
Spero Therapeutics CEO sells $63,352 in company stock By Investing.com - Investing.com Australia
Spero Therapeutics (SPRO) officer sells shares for RSU tax obligations - Stock Titan
Spero Therapeutics CEO sells $63,352 in company stock - Investing.com India
SPRO: The fleeting Sparrow - Moomoo
No call planned as Spero sets May 13 for Q1 results update - Stock Titan
Spero Therapeutics to Report First Quarter 2026 Financial Results and Provide Business Update on May 13, 2026 - GlobeNewswire
SPRO Stock Price, Quote & Chart | SPERO THERAPEUTICS INC (NASDAQ:SPRO) - ChartMill
Spero Therapeutics, Inc. (NASDAQ:SPRO) Sees Significant Growth in Short Interest - MarketBeat
Best Momentum Stock to Buy for October 10th - MSN
Spero Therapeutics (NASDAQ: SPRO) 2026 proxy adds stock increase and new incentive plan - Stock Titan
Spero Therapeutics (SPRO) price target decreased by 20.00% to 4.08 - MSN
[ARS] Spero Therapeutics, Inc. SEC Filing - Stock Titan
ROSEN, Top Ranked Investor Counsel, Encourages Spero Therapeutics, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class ActionSPRO - TMX Newsfile
Spero Therapeutics (SPRO) Stock Volume Spike Alert (Builds on Momentum) 2026-04-20Open Stock Picks - Cổng thông tin điện tử tỉnh Lào Cai
Spero Therapeutics (SPRO) Stock Insider Buying (Market Focus) 2026-04-18Algo Picks - Cổng thông tin điện tử tỉnh Lào Cai
SPRO Forecast, Price Target & Analyst Ratings | SPERO THERAPEUTICS INC (NASDAQ:SPRO) - ChartMill
Spero Therapeutics Stock Rises Above 50-Day Moving Average - National Today
Spero Therapeutics (NASDAQ:SPRO) Share Price Passes Above 50 Day Moving AverageWhat's Next? - MarketBeat
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):